Abstract
Hematopoietic stem cell transplantation (HSCT) is currently a standard-of-care procedure for many disorders to provide a potential cure in situations where no other curative treatment options exist. The key element in HSCT is the replacement of the host (recipient) marrow function by another source of hematopoietic stem cells (HSC), from either the patient or a human leukocyte antigen (HLA)-compatible family member or unrelated donor. In the setting of a donor HSCT, products are preferentially matched at major histocompatibility complex (MHC) HLA class I and II molecules located on chromosome 6, which guide immunologic recognition as self or nonself. Advances across the field have contributed to improvements in disease control and overall survival, resulting in a marked increase in the number of procedures performed annually worldwide.
It is also recognized that these patients still face a significant morbidity and mortality substantiating the continued need for ongoing research. There are many areas of active research encompassing all phases of the transplant procedure. However, with the advancements in technology comes challenges including workforce shortages and challenge in provision of long-term and survivorship care.
Keywords
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsBibliography
Burns LJ, Gajewski JL, Majhail NS, Navarro W, Perales MA, et al. Challenges and potential solutions for recruitment and retention of hematopoietic cell transplantation physicians: the National Marrow Donor Program’s System Capacity Initiative Physician Workforce Group Report. Biol Blood Marrow Transplant. 2014;20:617–21.
Copelan E. Hematopoietic stem-cell transplantation. N Engl J Med. 2006;354:1813–26.
Deeg J, DiPersio J, Young J, Maziarz R, Perreault C, Margolis D, et al. ASBMT policy statement 2009 research priorities. Biol Blood Marrow Transplant. 2009;15:1489–91.
Gajewski J, LeMaistre F, Silver S, Lill M, Selby G, Horowitz M, et al. Impending challenges in the hematopoietic stem cell transplantation physician workforce. Biol Blood Marrow Transplant. 2009;15:1493–501.
Giralt S, Arora M, Goldman J, Lee S, Maziarz R, McCarthy P, et al. Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia. Br J Haematol. 2007;135:461–7.
Horowitz M. The role of registries in facilitating clinical research in BMT: examples from the Center for International Blood and Marrow Transplant Research. Bone Marrow Transplant. 2008;42:S1–2.
Majhail NS, Murphy EA, Denzen EM, Ferguson SS, Anasetti C, Bracey A, et al. The National Marrow Donor Program’s Symposium on Hematopoietic Cell Transplantation in 2020: a healthcare resource and infrastructure assessment. Biol Blood Marrow Transplant. 2012;18:172–82.
Maus MV, Grupp SA, Porter DL, June CH. Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood. 2014;123:2625–535.
Weisdorf D, Carter S, Confer D, Ferrara J, Horowitz M. Blood and marrow transplant clinical trials network (BMT CTN): addressing unanswered questions. Biol Blood Marrow Transplant. 2007;13:257–62.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Maziarz, R. (2015). Overview of Hematopoietic Stem Cell Transplantation. In: Maziarz, R., Slater, S. (eds) Blood and Marrow Transplant Handbook. Springer, Cham. https://doi.org/10.1007/978-3-319-13832-9_1
Download citation
DOI: https://doi.org/10.1007/978-3-319-13832-9_1
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-13831-2
Online ISBN: 978-3-319-13832-9
eBook Packages: MedicineMedicine (R0)